Global Maxfin analyst Ralph Garcea says Espial Group (Espial Group Stock Quote, Chart, News: TSX:ESP) could deliver big returns to … [Read more...] about Espial Group is undervalued, says Global Maxfin analyst Ralph Garcea
Walter Isaacson author of the best-selling Steve Jobs biography, "Jobs" was on CNBC's "Squawk Box" this morning to talk about the differences between … [Read more...] about Apple’s problem is boring products, not Tim Cook, says Steve Jobs’ biographer
Part one of a three part series offering technical and business perspectives on the BlackBerry patent portfolio. Eyes have been on BlackBerry for … [Read more...] about BlackBerry Patents – Another Hi-Tech Treasure Trove?
Investors would be wise to stay away from Bombardier (Bombardier Stock Quote, Chart, News: TSX:BBD.B), says one fund manager. Brandon Osten, … [Read more...] about Stay away from Bombardier, says Venator Capital’s Osten
Following our article yesterday about cuts to BlackBerry's salesforce, several media outlets such as the Wall Street Journal, CNET, and The Next Web … [Read more...] about BlackBerry responds to our article on its salesforce cuts
According to a source close to the matter, BlackBerry today laid off more than half its salesforce. The source, based in Waterloo, says consumer … [Read more...] about BlackBerry just “gutted” its salesforce, this source says
Pop-up ads, seemingly personally addressed but actually generic banner ads. Pre-checked boxes that add services to the unwary internet user in a hurry … [Read more...] about Welcome to the wonderful world of “Zuckermining”. Resistance is futile.
The TSX's little brother, the TSX Venture Exchange, hasn't exactly been a thrill a minute lately. The unraveling of the mining and metals sector … [Read more...] about The 10 Hottest Tech Stocks on the TSX Venture Exchange Right Now
Another record quarter for Waterloo-based logistics firm Descartes Systems Group (Descartes Systems Group Stock Quote, Chart, News: TSX:DSG) has PI … [Read more...] about PI analyst Pardeep Sangha raises target on Descartes to $13
Dr. Chil-Yong Kang and his team at London-based University of Western Ontario are set to apply to the U.S. Food and Drug Administration for Phase II … [Read more...] about Western University-born HIV vaccine moves to Phase Two Trials